Synthesis of Quantum Logic Circuits

We discuss efficient quantum logic circuits which perform two tasks: (i) implementing generic quantum computations and (ii) initializing quantum registers. In contrast to conventional computing, the latter task is nontrivial because the state-space of an n-qubit register is not finite and contains exponential superpositions of classical bit strings. Our proposed circuits are asymptotically optimal for respective tasks and improve published results by at least a factor of two. The circuits for generic quantum computation constructed by our algorithms are the most efficient known today in terms of the number of expensive gates (quantum controlled-NOTs). They are based on an analogue of the Shannon decomposition of Boolean functions and a new circuit block, quantum multiplexor, that generalizes several known constructions. A theoretical lower bound implies that our circuits cannot be improved by more than a factor of two. We additionally show how to accommodate the severe architectural limitation of using only nearest-neighbor gates that is representative of current implementation technologies. This increases the number of gates by almost an order of magnitude, but preserves the asymptotic optimality of gate counts.Comment: 18 pages; v5 fixes minor bugs; v4 is a complete rewrite of v3, with 6x more content, a theory of quantum multiplexors and Quantum Shannon Decomposition. A key result on generic circuit synthesis has been improved to ~23/48*4^n CNOTs for n qubit

Minimal Universal Two-qubit Quantum Circuits

We give quantum circuits that simulate an arbitrary two-qubit unitary operator up to global phase. For several quantum gate libraries we prove that gate counts are optimal in worst and average cases. Our lower and upper bounds compare favorably to previously published results. Temporary storage is not used because it tends to be expensive in physical implementations. For each gate library, best gate counts can be achieved by a single universal circuit. To compute gate parameters in universal circuits, we only use closed-form algebraic expressions, and in particular do not rely on matrix exponentials. Our algorithm has been coded in C++.Comment: 8 pages, 2 tables and 4 figures. v3 adds a discussion of asymetry between Rx, Ry and Rz gates and describes a subtle circuit design problem arising when Ry gates are not available. v2 sharpens one of the loose bounds in v1. Proof techniques in v2 are noticeably revamped: they now rely less on circuit identities and more on directly-computed invariants of two-qubit operators. This makes proofs more constructive and easier to interpret as algorithm

Drug-Excipient Compatibility Studies in Formulation Development: Current Trends and Techniques

The safety, efficacy, quality and stability of a formulation are the cornerstones of any new drug development process. In order to consistently maintain these attributes in a finished dosage form, it is important to have a comprehensive understanding of the physico-chemical characteristics of the active pharmaceutical ingredient (API), as well as all other components (e.g. excipients, manufacturing aids, packaging materials) of the drug product. In a new drug development process, a detailed characterization of the API and other formulation components is usually carried out during the preformulation stage. The preformulation stage involves characterization of several aspects of the API including solubility, dissolution, permeability, polymorph/salt screening, stability (solidstate and solution-state), ionization properties, particle size distribution, API-excipient compatibilities etc. [1]. Excipients are ubiquitous to virtually every pharmaceutical formulation, and facilitate the manufacture, stability, administration, delivery of the API, and/or provide other functionalities to the dosage form. Excipients are used to improve processing (e.g. improving powder flow [2, 3], powder compactibility [4-6] etc.), enhance aesthetics (e.g. identification, branding etc. [7]), optimize product performance (e.g. modified drug-release [8-11]), and/or to facilitate patient compliance (e.g. taste masking [12-15]). They may constitute anywhere from 1 to 99 % of the total formulation mass. Due to the intimate contact of the API with one or more excipients in a formulation, there exists a likelihood of physical and/or chemical interactions between them. Any such interactions may result in a negative impact on the physical, stability or performance attributes of the drug product [16, 17]. The choice of excipients is of crucial importance to avoid these negative effects, and to facilitate the development of a robust and an effective formulation [18-20]. Thus, for a rational selection of excipients, screening of excipient-API compatibility is recognized as an important aspect of formulation development. Moreover, the USFDA’s 21st century current Good Manufacturing Practices (cGMP) initiative and International Council on Harmonization (ICH) Q8 guidelines encourage the pharmaceutical manufacturers to apply Quality by Design (QbD) principles in their drug development process [21, 22]. These guidelines include expectations of a clear understanding of any interactions between the formulation components. Moreover, recent advances in various thermal and non-thermal analytical techniques have led to an improved efficiency in the detection, monitoring and prevention of the incompatibilities early in the drug development process [23, 24]. This article aims to provide a brief overview of the nature of drug-excipient incompatibilities; as well as current trends and techniques used to evaluate these compatibilities in formulation development

A solid dispersion based on milk-micelle as a drug-carrier for the enhancement of the aqueous solubility of ritonavir

The goal of present investigation was to evaluate the feasibility of formulating a solid-dispersion using milk-micelles as drug-carriers, to enhance the aqueous solubility of ritonavir

Formulation of a drug-phospholipid complex (Naturosome) to enhance the aqueous solubility of standardized extract of Centella asiastica (SCE)

Purpose: To evaluate the enhancement of aqueous solubility of standardized extract of Centella asiastica, a natural drug with known anti- Alzheimer’s activity, by formulating its complex (Naturosome) with a phospholipid - Phospholipon® 90H

Isolated multiple cutaneous verruciform xanthomas

Verruciform xanthoma (VX) is a rare benign skin condition, primarily of the oral mucosa that can also affect the skin and genital mucosa. The etiology is not yet completely understood; though its association with conditions of chronic inflammation or trauma, chronic lymphedema, chronic graft versus host disease and CHILD syndrome are mentioned in the literature. Here, we report the case of multiple verruciform xanthomas on the bilateral forearms and upper back of a 25-year-old man in the absence of chronic skin disease or systemic disease and surprisingly, he didn’t have mucosal VX too. Histopathology of the lesion showed nodular dense infiltrate of foamy macrophages in the papillary dermis which stained positive for CD68

Emerging technologies for the non-invasive characterization of physical-mechanical properties of tablets

The density, porosity, breaking force, viscoelastic properties, and the presence or absence of any structural defects or irregularities are important physical-mechanical quality attributes of popular solid dosage forms like tablets. The irregularities associated with these attributes may influence the drug product functionality. Thus, an accurate and efficient characterization of these properties is critical for successful development and manufacturing of a robust tablets. These properties are mainly analyzed and monitored with traditional pharmacopeial and non-pharmacopeial methods. Such methods are associated with several challenges such as lack of spatial resolution, efficiency, or sample-sparing attributes. Recent advances in technology, design, instrumentation, and software have led to the emergence of newer techniques for non-invasive characterization of physical-mechanical properties of tablets. These techniques include near infrared spectroscopy, Raman spectroscopy, X-ray microtomography, nuclear magnetic resonance (NMR) imaging, terahertz pulsed imaging, laser-induced breakdown spectroscopy, and various acoustic- and thermal-based techniques. Such state-of-the-art techniques are currently applied at various stages of development and manufacturing of tablets at industrial scale. Each technique has specific advantages or challenges with respect to operational efficiency and cost, compared to traditional analytical methods. Currently, most of these techniques are used as secondary analytical tools to support the traditional methods in characterizing or monitoring tablet quality attributes. Therefore, further development in the instrumentation and software, and studies on the applications are necessary for their adoption in routine analysis and monitoring of tablet physical-mechanical properties